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Human thyroid peroxidase (TPO) has been purified from thyroid microsomes by immunoaffrnity chroma- 
tography using a monoclonal antibody (mAb) to TPO. The eluted material had a specific activity of 381 
U/mg and exhibited a peak in the Soret region. The ratio of A,,, to A,,, ranged from 0.20 to 0.25. Upon 
SDS-polyacrylamide gel electrophoresis, the purified enzyme gave two contiguous bands in the 100 kDa 
region. Further, it has been demonstrated that sera with anti-microsomal autoantibodies from patients 
presenting Graves’ or Hashimoto’s thyroiditis diseases were able to bind to purified TPO and to inhibit 
in a dose-dependent manner the mAb binding to purified TPO. This suggests that TPO is the thyroid antigen 
termed to date the microsomal antigen. 
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1. INTRODUCTION 
Thyroid peroxidase (TPO) plays a major role in 
biosynthesis of thyroid hormones [1,2]. Current 
methods for TPO purification allow one to recover 
only a few percent of the enzyme activity 13-81. 
Taken together with the scarcity of human tissue, 
this explains why no specific information is 
available on human TPO. Recently, TPO has been 
involved in autoimmune thyroid diseases [9,10] 
which are associated with the presence of autoan- 
tibodies (aAb) directed to various components of 
the gland [ 111. The nature of several of these au- 
toantigens remains unknown [ 111. 
In a previous paper, we have shown that the 
microsomal antigen is antigenically related to 
human TPO [lo]. Taking advantage of an anti- 
human TPO monoclonal antibody (mAb) pro- 
duced in our laboratory [lo, 121, we present here 
the first data on preparation and partial character- 
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ization of purified human TPO. Furthermore, we 
give evidence that TPO is an autoantigen recog- 
nized by anti-thyroid aAb and shares most of the 
properties attributed to the microsomal antigen 
[13-151. 
2. MATERIALS AND METHODS 
2.1. Preparation of solubilized human thyroid 
microsomes 
Human thyroid tissue was obtained from pa- 
tients undergoing surgery for various diseases of 
the gland. The microsomal fraction was prepared 
according to [6] with minor modification. 
Microsomes were incubated overnight at 4°C in 
50 mM Tris-HCl buffer (pH 7.8) containing 
0.1 mM KI and 0.3% sodium deoxycholate 
(DOC). After 100000 x g centrifugation for 1 h at 
4”C, the solubilized material was treated by a 
neutralized solution of (NH&S04 at 60% satura- 
tion. The precipitated material was dissolved in 
and extensively dialyzed against 10 mM Tris-HCl 
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buffer, pH 7.8, 0.1 mM KI. The preparation was 
stored at - 80°C until use. 
2.2. Affinity-purification of human TPO 
10 mg anti-TPO mAb was coupled to 5 ml 
CNBr activated Sepharose 4B (Pharmacia) accord- 
ing to the manufacturer’s instructions. 100 mg 
solubilized microsomes corresponding to 38 g 
thyroid tissue were passed through the affinity 
column previously equilibrated with 10 mM Tris- 
HCI buffer, pH 7.8, 0.1 mM KI, 0.5 M KC1 and 
0.1% DOC (buffer B.l). Washing was achieved 
with the previous buffer followed by 0.1 M borate 
buffer, pH 9.0, 0.1 mM KI, 1 M KC1 and 0.5% 
DOC (buffer B.2). Human TPO eluted with 0.1 M 
NHdOH, 0.1 mM KI, 1 M KC1 and 0.5% DOC 
(buffer B.3). The eluate fractions were extensively 
dialyzed against 10 mM Tris-HCl buffer, pH 7.5, 
0.1 m KI and stored in liquid nitrogen until use. 
2.3. TPO activity assay 
The enzymatic activity of TPO was measured us- 
ing the guaiacol assay [4]. Briefly samples contain- 
ing TPO were dissolved in 0.067 M phosphate buf- 
fer (pH 7.4) containing 40 mM guaiacol in a final 
volume of 2.0 ml. The reaction was initiated by ad- 
dition of Hz02 at a concentration giving 0.3 mM in 
the final volume. The assay was performed at 
room temperature. The oxidation of guaiacol was 
followed spectrophotometrically at 470 nm. One 
unit of the enzyme activity was defined to oxidize 
1 pmol of guaiacol/min [6]. 
2.4. Immunoprecipitation assay 
Sera from patients with Graves’ disease or 
Hashimoto’s thyroiditis were mixed with various 
amounts of affinity purified hTP0 in 10 mM Tris- 
HCI buffer (pH 7.5) in a total volume of 0.3 ml. 
After overnight incubation at 4°C samples were 
centrifuged at 10000 x g for 5 min. Supernatants 
were incubated with 0.5 ml protein A-Sepharose 
4B gel (Pharmacia) for 1 h at 4°C. After cen- 
trifugation 15 min at 2000 x g, TPO activity was 
measured in supernatants and precipitates. 
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Fig.1. Immunoaffinity chromatography profile of a crude preparation of the human thyroid peroxidase. The 
ammonium sulfate precipitated fraction (100 mg) was applied to 5 ml of the mAb-CNBr Sepharose column. The arrows 
indicate the buffers used: B.l = 10 mM Tris-HCl buffer, pH 7.8, 0.1 mM KI, 0.5 M KC1 and 0.1% DOC; B.2 = 0.1 M 
borate buffer, pH 9.0,O. 1 mM KI, 1 M KC1 and 0.5% DOC and B.3 = 0.1 M NHdOH, 0.1 mM KI, 1 M KC1 and 0.5% 
DOC. 
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2.5. Radioimmunoassay 
Affinity-purified hTP0 was coated overnight at 
4°C on flexible microtiter plates (Falcon). Each 
well received 50 pl of hTP0 solution at 
0.002 mg/ml in phosphate buffered saline, pH 7.3. 
After washing and saturation with bovine serum 
albumin, anti-hTP0 mAb was incubated alone or 
mixed with serial dilutions of patient’s sera for 
90 min at 37°C. After numerous washings, mAb 
binding to hTP0 was evidenced by incubating 
radiolabeled affinity purified F(ab)l sheep anti- 
mouse antibodies for 90 min at 37°C. After 
numerous washings, wells were dried, cut and 
counted. 
2.6. Other methods 
Electrophoresis in SDS-polyacrylamide slab gels 
(gradient 8- 18 (r/o) was achieved according to [ 161. 
Immunoblotting was carried out according to [17] 
and isoelectrofocusing according to [ 181. Protein 
concentration was determined by the method 
described in 1191. 
3. RESULTS 
The affinity-column procedure eliminated more 
than 99% of the proteins which appeared essential- 
ly devoid of TPO activity (fig.1). Elution with 
NH40H allowed recovery of the TPO activity. 
Noteworthy, the enzyme activity profile was 
almost superimposable on the immunoreactivity 
assayed with the mAb (fig.1). Assays for protein 
concentration and TPO activity were carried out at 
successive steps of the purification procedure 
(table 1). Data for the initial homogenate and the 
particulate fraction are not presented since there 
was too much interference with the guaiacol assay 
Table 1 
Activity of thyroid peroxidase at various stages of 
purification 
Stage of Total Total Specific Purifica- 
purification protein units activity. tion 
(mg) (U/mg) factor 
Microsomes 791 915 1.1 1 
Solubilisate 383 861 2.2 2 
Affinity chro- 
matography 1.6 610 381 331 
Fig.%. SDS-polyacrylamide gel electrophoresis of 
purified human thyroid peroxidase. Samples were 
treated with 5% 2-mercaptoethanol. After electrophore- 
sis gel was stained with Coomassie brilliant blue R-250. 
The numbers in the margin indicate the molecular 
masses (x 10W3) of the standards. 
in these crude preparations. On the basis of 
previous papers from other groups [3-61, a 
purification of about IO-fold over the starting 
material to microsomes may be assumed. Begin- 
ning with microsomes, the purification factor was 
331-fold. Therefore the overall purification would 
be about 3000- to 3500-fold. 
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Electrophoresis in SDS-polyac~lamide slab gels 
of TPO showed two contiguous bands of apparent 
molecular mass of about 95 and 105 kDa (fig.2). 
Immunoblotting of such gels using the mAb did 
not distinguish the two bands which appeared to 
retain the antigenicity toward the mAb. Further 
separation by isoelectrofocusing yielded two- 
dimensional electrophoretic patterns indicating 
that these two bands differed slightly by their pHi: 
pH 7.0-7.4 for the 105 kDa band and pH 6.5-7.2 
for the 95 kDa band. Absorption spectra of the 
purified TPO exhibited a peak in the Soret region 
which shifted from 411 to 422 nm by reducing 
agents. The A411 :A280 ratio was 0.20 to 0.25 while 
that for a commercial preparation of bovine lac- 
toperoxidase was 0.72. Preliminary experiments of 
adsorption-elution of the affinity-purified TPO on 
concanavalin A-Sepharose gel and assay for the 
enzyme activity demonstrated that human TPO is 
a glycoprotein. 
Sera from healthy subjects and patients with 
autoimmune thyroid diseases were assayed for 
their ability to immunoprecipitate the purified 
TPO. After incubation with the affinity-purified 
material, IgG were precipitated by protein A 
coupled-Sepharose and the TPO activity assayed in 
the supernatant. With normal sera, devoid of anti- 
microsomal and anti-thyroglobulin aAb, the im- 
munoprecipitation procedure elicited a decrease of 
about 20% in the TPO activity in the supernatant 
(fig.3). This result could be accounted for by some 
nonspecific precipitation or inhibition of TPO. In 
contrast, sera from patients with Graves’ disease 
or Hashimoto’s thyroiditis immunoprecipitated 
microromer I I I 
Titer of 
autoantibodios 
to 
thyrogbbulin 1 g , 
Normal Graves ’ Had&not0 ’ s 
disease thyroiditis 
Fig.3. Human thyroid peroxidase activity after precipitation by various sera from patients with Hashimoto’s and 
Graves’ diseases and normal subjects. Each bar represents individual serum. Anti-microsomal nd anti-Tg titers were 
measured by hemagglutination tests (Thymune M and Thymune T, Wellcome, Dartford). 
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TPO to an extent ranging from 30 to 100% of the 
initial enzyme amount. Noteworthy, the TPO im- 
munoprecipitating activity of sera matched the 
titer of anti-microsomal aAb and was not related 
to the titer of anti-thyroglobulin aAb (fig.3). 
The interaction of anti-microsomal autoan- 
tibodies with human TPO was further studied by 
experiments of inhibition of the mAb binding to 
purified TPO by pools of sera and purified IgG. 
As shown in fig.4, normal sera and IgG did not in- 
terfere with mAb binding to TPO. In contrast, 
pools of sera and IgG from patients with anti- 
microsomal aAb inhibited in a dose-dependent 
manner the binding of the anti-TPO mAb to the 
affinity-purified material (fig.4). 
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Fig.4. Inhibition of mAb binding to TPO by pools of 
sera (upper panel) and IgG (lower panel) from normal 
subjects and patients with Hashimoto’s and Graves’ 
diseases. The initial mAb binding was 3725 cpm. 
4. DISCUSSION 
The cumbersome procedures for purification of 
TPO involve numerous cumbersome steps [3-71. 
The availability of mAb to TPO allows one to 
purify the enzyme much more rapidly and with a 
higher yield than the procedures currently in use 
[8]. Another problem encountered in the purifica- 
tion of TPO is the choice of the solubilization 
method. The most successful method for solubiliz- 
ing TPO has been trypsin digestion in combination 
with detergents [3-61. This procedure, however, 
may lead to variable cleavages of the enzyme 
molecule and to purification of trypsin-modified 
TPO [7,8]. The procedure used here allows high 
purification (-3500-fold) of the native human 
TPO. This is obtained with a reasonable yield 
(-10 mg TPO/kg thyroid tissue). 
Upon SDS-polyacrylamide electrophoresis, 
TPO gives two contiguous bands of M, 95000 and 
105000 which differ by their pHi but retain their 
antigenicity toward the anti-TPO mAb. In keeping 
with previous reports on purified native porcine 
TPO [7,8], this could suggest hat TPO has suf- 
fered limited degradation by thyroid protease 
and/or glycosidases. Absorption spectra of 
purified human TPO compare well with those of 
bovine and porcine TPO [3-81. The ratio of absor- 
bance at 413 nm to that at 280 nm is about half 
that of purified trypsinized TPO [3-61 but similar 
to that of the native enzyme from porcine thyroid 
PI * 
Recognition of TPO by anti-thyroid aAb is un- 
questionably demonstrated by aAb immuno- 
precipitation of TPO activity, and inhibition of 
mAb binding to TPO. Immunoprecipitation of 
TPO activity by aAb in autoimmune thyroid 
diseases has been recently reported 191. However, 
the use of solubilized thyroid particulate fraction 
by these investigators is highly questionable. Effec- 
tively, aAb in thyroid diseases are directed against 
numerous antigens and coprecipitation of TPO 
with other autoantigens cannot be excluded. In our 
case, the TPO preparation used presents almost all 
the characteristics required in the literature for 
highly purified TPO [3-81. Accordingly, our ex- 
periments of immunoprecipitation clearly demon- 
strate, for the first time, the direct interaction of 
aAb with the TPO molecule. This finding is fur- 
ther confirmed by inhibition of mAb binding to 
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TPO by sera and IgG from patients with auto- 
immune thyroid diseases but not from normal 
subjects. 
Only recently have some characteristics of the 
microsomal antigen been disclosed 113-151. The 
microsomal antigen was reported as a glycoprotein 
of 105 kDa [ 14,151 present in the cytoplasm and on 
the apical membrane of human thyroid cells 
[ 1 l-131. Noteworthy, TPO has been localized on 
the apical border of thyroid follicular cells [20] and 
has been also found widely distributed in the 
cytoplasm [21]. It thus appears that TPO shares all 
the properties attributed to the microsomal an- 
tigen. Taking into account all the information 
available on the microsomal antigen and TPO, the 
data presented here strongly suggest hat human 
TPO would be the microsomal antigen involved in 
autoimmune thyroid diseases. 
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